Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (423)	5/3/1998 11:06:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 2135

The article on angiostatin/endostatin was even the lead headline in the Eugene (OR) Register Guard this morning. Rick Klausner even called it "the single most exciting thing on the horizon" for the treatment of cancer. Almost as good hype as the drugs for erectile function. IMHO, the news should make ENMD stand up and out this week.

To: muddphudd who wrote (423)	5/3/1998 4:35:00 PM
From: StockDoc	Read Replies (2) \| Respond to of 2135

This article is going to help shorters, but the data were out a year ago. People just don't read science. All concerns on feasibility (especially pharmaceutical grade and scale manufacturing of the required doseage form) still apply. Yes, GO ENMD, but the first data you wanna see is coming in 1999 (the earliest). Be patient unless you wanna sell. I still trust Folkman's quest for the Nobel prize, that's why I hold this stock. He'll do no B.S, and he'll get it even if this thing is not commercially doable. There are at least 36 other companies working hard in the field (all on other antiangiogenic compounds) with or without the help of Harvard level academic institutions (Scripps, Univ. Leuven, Oxford, U.C., etc.). One WILL succeed. Regards, StockDoc